Breast Cancer - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
- Trial of Four Schedules of Adjuvant Chemotherapy for Breast Cancer
(Posted: 03/30/2004, Updated: 11/22/2006) - This trial compares the effectiveness of four different treatment schedules using the drugs doxorubucin, cyclophosphomide, and paclitaxel in treating patients who have undergone surgery for stage l, ll, or lll breast cancer.
- Gene Therapy for Metastatic Cancer
(Posted: 11/21/2006) - In the trial, researchers will harvest normal T lymphocytes from patients' blood and modify these immune system cells to recognize p53 protein, a common hallmark of many cancers. The modified cells will be enriched in the laboratory and then infused back into the patients.
- Breast Cancer Treatment for Premenopausal Women
(Posted: 01/17/2006) - In this trial, premenopausal women with endocrine-responsive breast cancer will receive the drug triptorelin to suppress the function of their ovaries (induction of menopause) and long-term anti-estrogen therapy with either exemestane (an aromatase inhibitor), to inhibit the production of estrogen outside the ovaries, or tamoxifen, to block the growth-promoting effects of any estrogen that might be produced. Researchers hope to determine which anti-estrogen treatment will help premenopausal women whose ovarian function is being suppressed survive longer without a recurrence of their cancer.
- Allogeneic Stem Cell Transplantation for Metastatic Breast Cancer
(Posted: 11/22/2005) - In this study, researchers are investigating whether allogeneic stem cell transplantation (ASCT) followed by the infusion of donor Th2/Tc2 cells--a type of T lymphocyte that is able to suppress graft-versus-host disease--can be safely used to treat patients with metastatic breast cancer.
- Targeted Combination Therapy for Advanced Solid Tumors
(Posted: 07/19/2005) - In this study, researchers are assessing the safety and combined effectiveness of bevacizumab and a second drug called sorafenib. Both bevacizumab and sorafenib inhibit the formation of blood vessels to tumors and may act synergistically when combined.